CClinicalTrials.gg
Status unknownNCT02402374Updated Oct 8, 2020

Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer

An interventional study of Autologous platelet rich plasma gel and Placebo in Diabetic Foot Ulcers, sponsored by Regen Lab SA. Status unknown at 1 site in United States. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2020-10-08.

Sponsored by Regen Lab SA · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

Autologous platelet-rich plasma (PRP) gel was reported to have very good outcomes in the treatment of foot ulcers in pilot studies and retrospective uncontrolled trials. Therefore, a larger randomized, placebo-controlled clinical trial will be useful to determine whether platelet-rich plasma is safe and effective for the treatment of diabetic foot ulcers (DFU).

Read the detailed description

Evaluate the safety and efficacy of RegenKit autologous PRP Gel for the treatment of diabetic foot ulcer is a randomized, placebo controlled, blind-assessor study. One hundred and seventy four patients will be treated, 87 patients receiving treatment arm and 87 patients receiving placebo. The primary endpoint is to evaluate proportion of patients with complete wound closure at week 16 when treated with autologous platelet rich plasma gel compared to the proportion of control (saline gel) treated patients with complete wound closure at the same time-point.

02

Conditions studied

  • Diabetic Foot Ulcers
03

In context

Diabetic Foot

1,054 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

This study's planned enrollment of 192 is above the median of 60 across 826 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Regen Lab SA is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who in the opinion of the Investigator, are capable of understanding and complying with protocol requirements
  • Patients or, when applicable, their legal representatives, sign and dates a written IFC and/or any required privacy authorization prior to the initiation of any study procedure
  • Patients aged 18 to 95 (inclusive) with Type 1 or Type 2 diabetes undergoing therapy for glycemic control
  • Patients with glycated hemoglobin (HbA1C) less than or equal to 12%
  • Patients having ulcers which meet the following criteria:
  • Ulcer should not be infected as determined by clinical examination
  • Ulcer duration of 4 weeks or longer
  • Ulcer area (length x width) of between 1.5 cm2 and 20 cm2
  • Full-thickness ulcer of Grade 1 or Grade 2 as per Wagner's classification system
  • Ulcer has undergone recent debridement (2 weeks prior to screening)
  • Post-debridement ulcer is free of necrotic debris, foreign bodies, sinus tracts, tunneling, and undermining and is comprised of healthy vascularized tissue
  • Patients with Charcot deformity, the wound should be free of acute changes and, in the opinion of Investigator, should have undergone appropriate structural consolidation (the affected charcot fractures will have been fused together and should be sufficiently stable to allow the patient to weight-bear)
  • Patients having adequate circulation to the foot as documented by either:

    1. Ankle Brachial Index (ABI) between 0.60 and 1.30, or
    2. Patients with falsely elevated ABI values (equal to or greater than 1.30) due to non-compressible ankle vessels:

    i)Toe Brachial Index (TBI) equal to or greater than 0.50 or, ii)TBI is not available (toe is absent, wounds are present, or investigative site cannot perform a TBI), a Doppler waveform in the posterior tibial or dorsalis pedis arteries at the ankle consistent with adequate flow in the foot (biphasic or triphasic) and other diagnostic confirmation of adequate flow (e.g duplex imaging or normal pulse volume recording)

  • Patients who agree to conform to the off-loading requirements
  • Patients of childbearing age must agree to use a method of contraception or agree to abstain from sexual intercourse throughout the study

Exclusion criteria

Exclusion Criteria

  • Patients with ulcers having an active infection with/without purulent discharge
  • Patients with ulcers with exposed bone or associated with osteomyelitis
  • Patients with target limb cellulitis, or ischemic or gangrenous ulcers
  • Patients who have undergone, in the 2-week period prior to enrollment, treatment for DFU with any advanced treatment modality other than standard of care, such as growth factors, skin substitutes or other biological treatments
  • Female patients who are pregnant or lactating
  • Patients diagnosed with cancer, undergoing chemotherapy, except basal cell carcinoma
  • Patients with wounds caused by basal cell carcinoma or due to basal cell carcinoma excision
  • Patients with wounds due to malignancy
  • Patients having had any revascularization surgery within the 4-week period prior to signing the ICF
  • Patients with renal failure requiring dialysis
  • Patients with platelet count outside of the normal range of 150-400 x 1000/uL
  • Patients with a history of allergy to one of tested components
  • Patients with a history of bleeding disorders
  • Patients suffering from skin or blood cancers, or having suffered in the past from such cancers and not having, certification of a total remission
  • Patients presenting skin lesions potentially caused by abnormal cellular proliferation process (history of being cancerous)
  • Patients with a history of any condition, physical examination finding, or clinical laboratory finding, giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational agent or may confound the interpretation of study results or might render the patient at high risk for treatment complications
  • Patients with active Charcot or other structural deformity that would prevent adequate off-loading of the study foot
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    PRP gel

    Autologous platelet rich plasma gel

    Device: Autologous platelet rich plasma gel

  • Placebo comparator
    Placebo

    Saline gel

    Device: Placebo

Interventions

  • DeviceAutologous platelet rich plasma gel

    PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds

  • DevicePlacebo

    Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with complete wound closure

    Proportion of patients with complete wound closure at week 16 when treated with autologous platelet rich plasma gel compared to the proportion of control (saline gel)-treated patients with complete wound closure at the same time-point.

    Time frame: 16 weeks

07

Study locations

1 site
  • Futuro Clinical Trials
    McAllen, Texas 78501, United States
08

References and documents

Individual participant data

Plan to share: Yes — The Institution and the Principal Investigator are free to publish, present, or use any data and results arising out of this Study, provided that such publication does not disclose any of Sponsor's Confidential Information. Sponsor shall be able to present data and results at symposia, national or regional professional meetings, and publish in journals, theses or dissertations, or otherwise of its own choosing. In the event that the Principal Investigator fails to submit a formal academic publication within twelve (12) months following completion of the Study, the Sponsor is entitled to prepare a publication based on the data and results. Such proposed publication will be submitted to the Institution for review and comment at the least thirty (30) calendar days before submission for publication.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02402374
Lead sponsor
Regen Lab SA
Collaborators
RegenLab USA LLC
Responsible party
Sponsor
First posted
Mar 30, 2015
Start date
Apr 12, 2018
Primary completion
Oct 30, 2020 (estimated)
Completion
Dec 30, 2020 (estimated)
Last update
Oct 8, 2020

Study contacts

Alisha Oropallo, MD
principal investigator · Northwell Health, Comprehensive Wound Care Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion